Loss of Direct Vascular Contact to Astrocytes in the Hippocampus as an Initial Event in Alzheimer’s Disease. Evidence from Patients, In Vivo and In Vitro Experimental Models

Wu T, Lin D, Cheng Y, Jiang S, Riaz MW, Fu N, Mou C, Ye M et al (2022) Amyloid cascade hypothesis for the treatment of Alzheimer’s disease: progress and challenges. Aging Dis 13:1745–1758 Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185 Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608 Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16:30–42 Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys 301:41–52 Yamada M (2015) Cerebral amyloid angiopathy: emerging concepts. J Stroke 17:17–30 Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, and Initiative Alzheimer’s Disease Neuroimaging (2016) Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 7:11934 Jha NK, Jha SK, Kar R, Nand P, Swati K, Goswami VK (2019) Nuclear factor-kappa beta as a therapeutic target for Alzheimer’s disease. J Neurochem 150:113–137 Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 17:157–172 Koerich S, Parreira GM, de Almeida DL, Vieira RP, de Oliveira ACP (2023) Receptors for advanced glycation end products (RAGE): promising targets aiming at the treatment of neurodegenerative conditions. Curr Neuropharmacol 21:219–234 Park R, Kook SY, Park JC, Mook-Jung I (2014) Abeta1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-kappaB signaling. Cell Death Dis 5:e1299 Tolstova AP, Adzhubei AA, Mitkevich VA, Petrushanko IY, Makarov AA (2022) ‘Docking and molecular dynamics-based identification of interaction between various beta-amyloid isoforms and RAGE receptor’. Int J Mol Sci 23 Beauquis J, Homo-Delarche F, Giroix MH, Ehses J, Coulaud J, Roig P, Portha B, De Nicola AF et al (2010) Hippocampal neurovascular and hypothalamic-pituitary-adrenal axis alterations in spontaneously type 2 diabetic GK rats. Exp Neurol 222:125–134 Diniz Pereira J, Gomes Fraga V, Morais Santos AL, Carvalho MDG, Caramelli P, Braga Gomes K (2021) Alzheimer’s disease and type 2 diabetes mellitus: a systematic review of proteomic studies. J Neurochem 156:753–776 Vinuesa A, Pomilio C, Gregosa A, Bentivegna M, Presa J, Bellotto M, Saravia F, Beauquis J (2021) Inflammation and insulin resistance as risk factors and potential therapeutic targets for Alzheimer’s disease. Front Neurosci 15:653651 Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12:723–738 Bardehle S, Krüger M, Buggenthin F, Schwausch J, Ninkovic J, Clevers H, Snippert HJ, Theis FJ et al (2013) Live imaging of astrocyte responses to acute injury reveals selective juxtavascular proliferation. Nat Neurosci 16:580–586 Horng S, Therattil A, Moyon S, Gordon A, Kim K, Argaw AT, Hara Y, Mariani JN et al (2017) Astrocytic tight junctions control inflammatory CNS lesion pathogenesis. J Clin Invest 127:3136–3151 Heithoff BP, George KK, Phares AN, Zuidhoek IA, Munoz-Ballester C, Robel S (2021) Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Glia 69:436–472 Yue Q, Hoi MPM (2023) Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer’s disease. Neural Regen Res 18:1890–1902 Arranz AM, De Strooper B (2019) The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol 18:406–414 Presa JL, Saravia F, Bagi Z, Filosa JA (2020) Vasculo-neuronal coupling and neurovascular coupling at the neurovascular unit: impact of hypertension. Front Physiol 11:584135 Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53 Demene C, Tiran E, Sieu LA, Bergel A, Gennisson JL, Pernot M, Deffieux T, Cohen I et al (2016) 4D microvascular imaging based on ultrafast Doppler tomography. Neuroimage 127:472–483 Johnson AC (2023) Hippocampal vascular supply and its role in vascular cognitive impairment. Stroke 54:673–685 Soto-Rojas LO, Pacheco-Herrero M, Martinez-Gomez PA, Campa-Cordoba BB, Apatiga-Perez R, Villegas-Rojas MM, Harrington CR, de la Cruz F et al (2021) ‘The neurovascular unit dysfunction in Alzheimer’s disease’. Int J Mol Sci 22 Wan W, Cao L, Liu L, Zhang C, Kalionis B, Tai X, Li Y, Xia S (2015) Abeta(1–42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem 134:382–393 Yao D, Zhang R, Xie M, Ding F, Wang M, Wang W (2023) Updated understanding of the glial-vascular unit in central nervous system disorders. Neurosci Bull 39:503–518 Eisenmenger LB, Peret A, Famakin BM, Spahic A, Roberts GS, Bockholt JH, Johnson KM, Paulsen JS (2023) Vascular contributions to Alzheimer’s disease. Transl Res 254:41–53 Dorr A, Sahota B, Chinta LV, Brown ME, Lai AY, Ma K, Hawkes CA, McLaurin J et al (2012) Amyloid-beta-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135:3039–3050 Kimbrough IF, Robel S, Roberson ED, Sontheimer H (2015) Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer’s disease. Brain 138:3716–3733 Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC et al (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7:609–618 Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE (2000) Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer’s disease. Mol Med 6:430–439 Scheffer S, Hermkens DMA, van der Weerd L, de Vries HE, Daemen M (2021) Vascular hypothesis of alzheimer disease: topical review of mouse models. Arterioscler Thromb Vasc Biol 41:1265–1283 Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA et al (2006) Reversal of Alzheimer’s-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 103:7130–7135 Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC et al (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 96:3228–3233 Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D et al (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050–4058 Beauquis J, Vinuesa A, Pomilio C, Pavia P, Galvan V, Saravia F (2014) Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer’s disease. Hippocampus 24:257–269 Lin AL, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, Javors M, Shih YY et al (2013) Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. J Cereb Blood Flow Metab 33:1412–21 Simon AM, Schiapparelli L, Salazar-Colocho P, Cuadrado-Tejedor M, Escribano L, de Maturana RL, Del Rio J, Perez-Mediavilla A et al (2009) Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol. Dis. 33:369–78 Stins MF, Gilles F, Kim KS (1997) Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 76:81–90 Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33 Miraglia MC, Rodriguez AM, Barrionuevo P, Rodriguez J, Kim KS, Dennis VA, Delpino MV, Giambartolomei GH (2018) Brucella abortus Traverses brain microvascular endothelial cells using infected monocytes as a Trojan horse. Front Cell Infect Microbiol 8:200 Benda P, Lightbody J, Sato G, Levine L, Sweet W (1968) Differentiated rat glial cell strain in tissue culture. Science 161:370–371 Ajit D, Udan ML, Paranjape G, Nichols MR (2009) Amyloid-beta(1–42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. Biochemistry 48:9011–9021 Paranjape GS, Gouwens LK, Osborn DC, Nichols MR (2012) Isolated amyloid-beta(1–42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. ACS Chem Neurosci 3:302–311 Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558–567 Gregosa A, Vinuesa A, Todero MF, Pomilio C, Rossi SP, Bentivegna M, Presa J, Wenker S et al (2019) Periodic dietary restriction ameliorates amyloid pathology and cognitive impairment in PDAPP-J20 mice: potential implication of glial autophagy. Neurobiol Dis 132:104542 Lagenaur C, Lemmon V (1987) An L1-like molecule, the 8D9 antigen, is a potent substrate for neurite extension. Proc Natl Acad Sci U S A 84:7753–7757 Pomilio C, Pavia P, Gorojod RM, Vinuesa A, Alaimo A, Galvan V, Kotler ML, Beauquis J et al (2016) Glial alterations from early to late stages in a model of Alzheimer’s disease: evidence of autophagy involvement in Abeta internalization. Hippocampus 26:194–210 Apatiga-Perez R, Soto-Rojas LO, Campa-Cordoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, Ontiveros-Torres MA, Bravo-Munoz M et al (2022) Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metab Brain Dis 37:39–50 Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE et al (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85:296–302 Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM (2011) Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 122:293–311 Jones RS, Minogue AM, Connor TJ, Lynch MA (2013) Amyloid-beta-induced astrocytic phagocytosis is mediated by CD36, CD47 and RAGE. J Neuroimmune Pharmacol 8:301–311 Villarreal A, Seoane R, Gonzalez Torres A, Rosciszewski G, Angelo MF, Rossi A, Barker PA, Ramos AJ (2014) S100B protein activates a RAGE-dependent autocrine loop in astrocytes: implications for its role in the propagation of reactive gliosis. J Neurochem 131:190–205 Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377–1392 Yeung JHY, Calvo-Flores Guzman B, Palpagama TH, Ethiraj J, Zhai Y, Tate WP, Peppercorn K, Waldvogel HJ et al (2020) Amyloid-beta(1–42) induced glutamatergic receptor and transporter expression changes in the mouse hippocampus. J Neurochem 155:62–80 Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med 68:413–430 Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB (2022) Aducanumab therapy to treat Alzheimer’s disease: a narrative review. Int J Alzheimers Dis 2022:9343514 Dhillon S (2021) Aducanumab: First Approval. Drugs 81:1437–1443 Avgerinos KI, Ferrucci L, Kapogiannis D (2021) Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev 68:101339 Fillit H, Green A (2021) Aducanumab and the FDA - where are we now? Nat Rev Neurol 17:129–130 Foley KE, Wilcock DM (2022) Vascular considerations for amyloid immunotherapy. Curr Neurol Neurosci Rep 22:709–719 Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131:3299–3310 Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z (2009) Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol 175:2099–2110 Mo JJ, Li JY, Yang Z, Liu Z, Feng JS (2017) Efficacy and safety of anti-amyloid-beta immunotherapy for Alzheimer’s disease: a systematic review and network meta-analysis. Ann Clin Transl Neurol 4:931–942 Wang YJ (2014) Alzheimer disease: lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10:188–189 Kirabali T, Rust R, Rigotti S, Siccoli A, Nitsch RM, Kulic L (2020) Distinct changes in all major components of the neurovascular unit across different neuropathological stages of Alzheimer’s disease. Brain Pathol 30:1056–1070 Wang J, Fan DY, Li HY, He CY, Shen YY, Zeng GH, Chen DW, Yi X et al (2022) Dynamic changes of CSF sPDGFRbeta during ageing and AD progression and associations with CSF ATN biomarkers. Mol Neurodegener 17:9 Sweeney MD, Ayyadurai S, Zlokovic BV (2016) Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci 19:771–783 Kisler K, Nelson AR, Rege SV, Ramanathan A, Wang Y, Ahuja A, Lazic D, Tsai PS et al (2017) Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci 20:406–416 ‘2023 Alzheimer’s disease facts and figures’ (2023) Alzheimers Dement 19:1598–695 Duncombe J, Lennen RJ, Jansen MA, Marshall I, Wardlaw JM, Horsburgh K (2017) Ageing causes prominent neurovascular dysfunction associated with loss of astrocytic contacts and gliosis. Neuropathol Appl Neurobiol 43:477–491 Hussong SA, Banh AQ, Van Skike CE, Dorigatti AO, Hernandez SF, Hart MJ, Ferran B, Makhlouf H et al (2023) Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy. Nat Commun 14:2367 Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE et al (2014) Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 9:28 Liu Y, Hu PP, Zhai S, Feng WX, Zhang R, Li Q, Marshall C, Xiao M et al (2022) Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer’s disease. Neural Regen Res 17:2079–2088 Robertson RT, Levine ST, Haynes SM, Gutierrez P, Baratta JL, Tan Z, Longmuir KJ (2015) Use of labeled tomato lectin for imaging vasculature structures. Histochem Cell Biol 143:225–234 Zeng F, Liu Y, Huang W, Qing H, Kadowaki T, Kashiwazaki H, Ni J, Wu Z (2021) Receptor for advanced glycation end products up-regulation in cerebral endothelial cells mediates cerebrovascular-related amyloid beta accumulation after Porphyromonas gingivalis infection. J Neurochem 158:724–736